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Summary objectives To compare the efﬁcacy and tolerability of dihydroartemisinin–piperaquine
(DHA–PQP) with that of a 3-day regimen of meﬂoquine and artesunate (MAS3) for the treatment of
uncomplicated falciparum malaria in Cambodia.
method Randomized open-label non-inferiority study over 64 days.
results Four hundred and sixty-four patients were included in the study. The polymerase chain
reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% conﬁdence interval, CI,
93.8–99.3) for DHA–PQP and 97.5% (95% CI, 93.8–99.3) for MAS3, P ¼ 1. There were no serious
adverse events, but signiﬁcantly more episodes of vomiting (P ¼ 0.03), dizziness (P ¼ 0.002),
palpitations (P ¼ 0.04), and sleep disorders (P ¼ 0.03) reported in the MAS3 treatment group,
consistent with the side-effect proﬁle of meﬂoquine.
conclusions DHA–PQP was as efﬁcacious as MAS3, but much better tolerated, making it more
appropriate for use in a routine programme setting. This highly efﬁcacious, safe and more affordable
ﬁxed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in
Cambodia.
keywords efﬁcacy, tolerability, dihydroartemisinin–piperaquine, falciparum malaria
Introduction
Malaria remains one of the most important causes of
morbidity and mortality in Cambodia with about 13% of
the population living in areas of malaria transmission.
Multidrug-resistant falciparum strains are common, par-
ticularly in the western provinces that share borders with
Thailand (Price et al. 2004). In 2003, the Ministry of
Health reported a total of 132 572 new cases of malaria,
82% of which were caused by Plasmodium falciparum.
There were 492 malaria-related deaths (Chatterjee 2005).
As a considerable proportion of malaria patients are
treated in private clinics, these ﬁgures (conﬁned to the
public health system) underestimate the real prevalence
and mortality of malaria.
Worldwide, antimalarial drug resistance is increasing
and the latest malaria treatment guidelines published by
the World Health Organization (WHO) recommend
artemisinin-based combination therapy (ACT) as ﬁrst-line
treatment for all patients with falciparum malaria (WHO
2006).
In Asia, artesunate and meﬂoquine has been the most
widely used artemisinin-based antimalarial combination in
areas of multidrug resistance (Nosten et al. 2000; WHO
2003). In 2001, the National Centre for Malaria Control
in Cambodia changed the national protocol for the
treatment of uncomplicated falciparum malaria to a 3-day
regimen of meﬂoquine and artesunate (MAS3). However,
in practice, patients may take one drug without the
other. Use of meﬂoquine as monotherapy is likely to lead to
an increase in meﬂoquine resistance. Yeung et al. (2004)
described a survey in Cambodia which found that more
than 80% of the patients with possible malaria sought
treatment in the informal sector. Of the antimalarial
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derivative, but only 20% of these were taken in combina-
tion with meﬂoquine as recommended.
Poor tolerability of meﬂoquine is a cause for concern
which has been well documented in Cambodia and
explicitly mentioned in the 2002 National Malaria Treat-
ment Guidelines of the Cambodian Ministry of Health.
Previous studies have often designated the related adverse
events as being self-limiting and graded them as mild to
moderate, with a negligible overall impact on treatment
adherence and efﬁcacy (ter Kuile et al. 1995; Ezedinachi
et al. 1999; Krudsood et al. 2002). Based on ﬁeld experi-
ence in Cambodia and Thailand, we are inclined to believe
that adverse effects such as vomiting, dizziness and sleep
disturbances are frequent enough to threaten correct
adherence to meﬂoquine-containing treatments. The fact
that meﬂoquine and artesunate are not available in a ﬁxed-
dose combination also makes non-adherence and the
emergence of resistance more likely.
Dihydroartemisinin–piperaquine (DHA–PQP), currently
developed and produced in China, is among the most
promising of new ACT regimens. Recent studies in
Thailand found excellent efﬁcacy and good tolerability
(Ashley et al. 2004, 2005). The regimen is available as a
ﬁxed-dose formulation of both drugs, which makes it easier
for self-administration and may have a favourable impact
on adherence to treatment. The cost of the treatment,
which at the time of this study was approximately 1.2 US
Dollars (USD) per adult treatment, is considerably lower
than the market price of MAS3 of about 3 USD. This large
ﬁeld-based study aimed to determine the efﬁcacy and
tolerability of this new combination antimalarial treatment
when compared with MAS3.
Methods
Study setting and population
The study was conducted at two sites: Anlong Veng, in
Oddar Meanchey province with a population of 13 578
inhabitants and Kvav, in Siem Reap province with a
population of 8017 inhabitants. Malaria transmission in
these two areas is low and seasonal. Me ´decins Sans
Frontie `res (MSF) has supported health care delivery in both
localities for several years, with a particular focus on
improving the quality of diagnosis and treatment of
malaria.
Between October 2002 and March 2003, patients were
recruited from consultations conducted at the health
centres or their outreach malaria clinics. These clinics are
run by nurses of the Ministry of Health.
The sample size was calculated to be at least 217 cases in
each treatment group to show non-inferiority in the
therapeutic efﬁcacy at 63 days of DHA–PQP vs. MAS3.
This calculation was based on an estimated therapeutic
efﬁcacy in the MAS3 group of 98% and the capacity to
detect a difference between the two groups of less than 5%
(to remain above the 90% of efﬁcacy recommended by the
World Health Organization) with 90% power and a two-
sided 5% signiﬁcance level, taking into account 10% loss
to follow-up and 20% of vivax appearance.
All individuals with signs and/or symptoms of uncom-
plicated malaria (fever at presentation or history of fever
within the last 24 h), and biological conﬁrmation by the
rapid diagnostic test (Paracheck PF
TM) were eligible for
screening. The main criteria for study inclusion were: age
greater than 1 year, history of fever or presence of fever
(axillary temperature P 37.5  C), and written informed
consent to participate in the study. Patients with mixed
infection of Plasmodium vivax or Plasmodium malariae
with P. falciparum were included. Excluded from the study
were pregnant or lactating mothers, and anyone with the
following: asexual stage parasitemia greater or equal to
4% red blood cells (approximately 175 000 parasites/ll),
signs or symptoms of severe malaria, a history of convul-
sions or a neuropsychiatric disorder or a history of
treatment with meﬂoquine in the past 60 days. Figure 1
illustrates the patient recruitment and ﬂow in the trial.
The study received ethical clearance from the National
Ethical Review Committee of the Ministry of Health in
Cambodia and the ethical review board of MSF.
Drugs and treatment regimens
Patients were allocated randomly to receive one of the
treatments using a computer-generated randomization
(stata version 8, StataCorp, college station, TX 77845,
USA). Treatment allocations were concealed in sealed
envelopes.
• Dihydroartemisinin–piperaquine (DHA–PQP
TM;
Holleykin Pharmaceutical Co. Ltd, Guangzhou,
China). One tablet of DHA–PQP contains 40 mg of
DHA and 320 mg PQP. An adult dose consisted of
four doses of two tablets, given at 0, 8, 24 and 48 h.
The approximate total adult dose was 6/48 mg/kg
(DHA/PQP). For children, a dose of 1.6/12.8 mg/kg
was given at the same time intervals; this dosage
was obtained by suspension of a DHA–PQP tablet in
5 ml of water.
• Artesunate + meﬂoquine for 3 days, as pre-packed
drugs (Ministry of Health, Cambodia). Artesunate
(Guillin, China, 50 mg tablets) and meﬂoquine
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received a ﬁxed regimen of 500 mg of meﬂoquine and
100 mg of artesunate twice daily on day 0 and
200 mg of artesunate once daily on day 1 and day 2.
The target dose for children was 4 mg/kg body weight
artesunate daily for 3 days and 25 mg/kg body weight
meﬂoquine split into two doses at least 8 h apart on
the ﬁrst day. The exact dosage was calculated and
given to the nearest quarter tablet. This was crushed
and mixed with liquid for children who were unable
to swallow tablets.
Both treatments were administered under direct obser-
vation. Each dose was repeated in full if vomiting
occurred within 30 min of administration, or halved if
vomiting occurred between 30 min and 1 h of drug
administration.
Clinical and laboratory monitoring
Enrolled patients were admitted to the trial centre for the
3-day period of treatment. All subjects were given a unique
code. Clinical and biological parameters were recorded,
including axillary temperature, parasitemia and haemato-
crit (Hct). A blood spot was collected on Whatmann 3M
chromatography paper for PCR genotyping in the event of
parasite reappearance. Baseline symptoms were screened
for actively on day 0 using a questionnaire with 20 possible
symptoms. From day 1 to day 3, the clinical evaluation was
repeated and the same symptom questionnaire was com-
pleted to record adverse events. These were deﬁned as any
new sign or symptom after the ﬁrst dose of drug had been
taken. Patients were monitored daily until fever clearance
and by blood microscopy until parasite clearance. There-
Figure 1 Patient recruitment and ﬂow.
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when axillary temperature was recorded, a symptom
questionnaire was completed, a malaria smear examined
and Hct measured. Medical ofﬁcers of the MSF team
conducted home visits for patients who did not attend a
scheduled visit. Any additional medications taken during
the trial period were documented.
In case of parasite reappearance, a new capillary blood
sample was taken from the patient onto ﬁlter paper to
perform PCR genotyping that tested for allelic variation in
three loci: merozoite surface proteins (MSP-1 & MSP-2)
and glutamate-rich protein in order to distinguish recru-
descence from reinfection. Infections with the same three-
locus genotype pre- and post-treatment with P (match)
<0.05, when compared with the prevalence of that
genotype frequency in the parasite population from this
area, were considered as recrudescent infections
(Brockman et al. 1999).
Patients previously treated with DHA–PQP were trea-
ted with MAS3 if there was no contraindication. Patients
who had received MAS3 were treated with artesunate
2 mg/kg and doxycycline 4 mg/kg daily for 7 days.
Children under the age of 8 received 2 mg/kg artesunate
daily for 7 days. Patients with a positive blood smear for
P. vivax, P. malariae or both were given chloroquine
(25 mg base per kg divided over 3 days) and follow-up
was continued.
Statistical methods
Data were entered and analysed using epi-info 6.4 (centres
for Disease Control and Prevention, Atlanta Georgia, USA)
and the stata software (version no. 8 StataCorp, college
station, TX 77845, USA). The primary end points were the
PCR-adjusted cure rates at day 63. Following established
guidelines (Piaggio et al. 2006), the cure rates were
analysed in a per-protocol (PP) analysis and an intention-
to–treat (ITT) analysis, where all randomized patients who
had received treatment were included. Cases of indeter-
minate PCR were considered as recrudescent infections,
adopting a worst-case scenario approach.
Overall, event-free survival distributions for both treat-
ment groups were estimated using the Kaplan–Meier
method and compared using the Cox-Mantel (log-rank)
test. Patients who did not complete follow-up or had a new
Plasmodium infection (P. falciparum, P. vivax or
P. malariae) were censored at the time they were last seen
for the primary outcome. With the same principle, cure
rates in each treatment arm were also calculated as an
incidence rate at each day of follow-up. In this approach,
the difference of the cure rates at day 63 were calculated
and the conﬁdence intervals (CIs) of those differences
were calculated by the Score method (Newcombe 1998).
This method allows comparing the difference between
the incidence of treatment success for both treatments
and the CI around this difference to demonstrate non-
inferiority.
Baseline characteristics of patients were compared using
the chi-squared or Fisher’s exact test for categorical
variables and by anova or the Kruskal–Wallis test for
continuous variables. All P values were two sided and the
level of signiﬁcance was set at P ¼ 0.05 or less. 95% CIs
were used throughout.
Safety and tolerability endpoints were the incidence of
adverse events, in the ﬁrst 3 days after the start of the
treatment. Differences in proportions were compared using
the two-sided chi-squared test.
Results
Characteristics of the study population
Four hundred and sixty-four patients were included in the
two sites; of whom 236 were assigned to receive MAS3 and
228 to receive DHA–PQP (Figure 1).
Seven patients were excluded from the analysis: 6 (1.3%)
were found to be smear negative after laboratory quality
control conﬁrmed by PCR and one patient developed signs
of severe malaria and was given rescue therapy. Twelve
patients (2.6%) were hyperparasitemic, and one patient
had a Hct of less than 15%; these were excluded from the
PP analysis. Forty-eight (10.3%) patients failed to com-
plete the 9-week follow-up. One of these patients withdrew
consent. The percentages of patients lost to follow-up were
similar between the treatment groups (P ¼ 0.8). Baseline
characteristics of the study populations are summarized in
Table 1. Both groups were comparable and there were no
major differences noted between the patients recruited at
each site.
Efﬁcacy and treatment outcomes
Both treatments show very high cure rates. There were 43
reappearances of falciparum malaria during the follow-up
period in the ITT analysis (38 in the PP analysis) (Table 2).
The comparison of the parasite genome of these cases with
the baseline PCR results identiﬁed 34 cases (in ITT, 30 in
PP) to be novel infections and eight cases (in ITT, seven
in PP) to be recrudescent infections (four (both analyses) in
the DHA–PQP group and four (in ITT, three in PP) in the
MAS3 group). For one infection, we were unable to deﬁne
a three-locus genotype due to inability to amplify all three
genes despite repeated attempts, this patient (MAS3 group)
was considered to have a recrudescent infection. All
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analysis at 63 days, the PCR-adjusted success rate was
97.5% (158/162) (95% CI, 93.8–99.3) in the DHA–PQP
group and 97.5% (158/162) (95% CI, 93.8–99.3) in the
MAS3 group (difference 0.0%, 95% CI, )4.0 to +4.0). A
Kaplan–Meier survival analysis with log rank test for
signiﬁcance estimated similar cure rates: 98.0% (95% CI,
94.6–99.2) for DHA–PQP and 97.6% (95% CI, 93.8–
99.1) for MAS3 (P ¼ 0.9) (Figure 2). In the ITT analysis,
the cure rate adjusted by the PCR results was 97.9% (189/
193) (95% CI, 94.8–99.4) in the DHA–PQP group and
97.4% (190/195) (95% CI, 94.1–99.2) in the MAS3 group
(difference +0.5%, 95% CI, )3.0 to +4.0). Kaplan–Meier
survival analysis gave a cure rate of 98.1% (95% CI,
95.0–99.3) for DHA–PQP and 97.5% (95% CI, 94.1–
99.0) for MAS3 (P ¼ 0.8). In both, the ITT and PP
analyses, the CI for differences were within the 5% limits
to satisfy statistical criteria for non-inferiority of
DHA–PQP to MAS3.
Mixed infections
At baseline, 21 patients had mixed infections, 19 with
P. vivax and two with P. malariae. By day 3, all patients
were free of P. vivax and P. malariae. During the
course of the trial, infections with P. vivax malaria were
detected in 86 patients (in ITT analysis, 80 in PP), 47
(in ITT, 44 in PP) in the MAS3 group and 39 (in ITT,
36 in PP) in the DHA–PQP group, in one patient an
infection of P. malariae was detected. Table 3 describes
the time of occurrence of these infections during the
course of the trial.
Fever and parasite clearance
On day 0, the proportions of the patients with fever
(axillary temperature P37.5  C) were comparable
between the MAS3 group (67.2%) and the DHA–PQP
group (67.9%). On day 1, 32.3% of the patients treated
with MAS3 still had fever compared with only 22.8% of
the group treated with DHA–PQP (P ¼ 0.025). On day 2,
the proportion of patients treated with MAS3 left with
fever was 7.0%, compared with 2.3% among the patients
treated with DHA–PQP (P ¼ 0.02).
Patients in the DHA–PQP group cleared their parasites
more quickly on day 1 of treatment with 62% of all
patients cleared of parasites compared with 49% of the
MAS3 arm (P ¼ 0.005). By day 2, more than 94% of the
patients in both groups had cleared their parasites.
95.0%
96.0%
97.0%
98.0%
99.0%
100.0%
7 1 42 12 83 54 24 95 66 3
DHA-PQP
MAS3
Figure 2 Kaplan–Meier curve on a PP analysis of the PCR-
adjusted cure rates for both treatment groups over the 63-day
follow-up.
Table 2 Appearance of Plasmodium falciparum, differentiated by
polymerase chain reaction (PCR) between novel and recrudescent
infections
No. of cases by day after treatment initiation
Day
7
Day
14
Day
21
Day
28
Day
35
Day
42
Day
49
Day
56
Day
63 Total
P. falciparum novel infections
DHA–PQP – – – 1 (–) 3 3 2 5 (2) 4 18 (14)
MAS3 – – 1 – 3 3 5 2 2 16 (16)
P. falciparum Novel + recrudescent
DHA–PQP – – – 1 1 – 1 – – 3 (3)
MAS3 – – – – – – 1 – 1 2 (2)
P. falciparum recrudescent infection
DHA–PQP – – – 1 – – – – – 1 (1)
MAS3 – – – – 1 – – – 2 3
DHA–PQP, dihydroartemisinin–piperaquine; MAS, Artesunate–
meﬂoquine.
In one case, PCR results were indeterminate and this case was
considered as recrudescent in the analysis.
Analysis presented for the ITT analysis and values in () for the PP
analysis
Table 1 Baseline characteristics of all patients included in the trial
MAS3
a DHA–PQP
b
Males, n (%) 163 (71.2) 150 (69.8)
Age (years), median (range) 21 (1–57) 21 (2–65)
Weight (kg), median (range) 48 (8–68) 47 (9–73)
Fever duration before
admission (days),
median (range)
3 (1–30) 3 (0–15)
Geometric mean
parasitemia (per ll)
4786 3311
(range) (30–158256) (40–173328)
Haematocrit % mean (SD) 35.7 (6.7) 35.6 (6.9)
Total 229 215
aArtesunate–Meﬂoquine.
bDihydroartemisinin–piperaquine.
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Patients in both treatment groups showed similar haema-
tological recovery during the 63-day follow-up period.
For the MAS3 group, the mean (SD) Hct rose from 35.7%
(6.7) at day 0 to 40.2% (3.8) at day 63; in the DHA–PQP
group, this increase went from 35.6% (6.8) on day 0 to
40.0% (3.7) on day 63.
Safety and adverse events
No serious adverse events were reported during this study,
but many patients reported lesser adverse events (the
majority of which were difﬁcult to differentiate from
symptoms of malaria). Table 4 presents the proportion of
patients reporting symptoms on the ﬁrst 3 days after the
start of the treatment. A signiﬁcantly higher proportion
of patients from the MAS3 group reported vomiting
(P ¼ 0.03), dizziness (P ¼ 0.002), palpitations (P ¼ 0.04)
and sleep disorders (P ¼ 0.03) than in the DHA–PQP
group.
If we consider all symptoms reported since day 0, we see
that for every symptom the proportions of patients who
report episodes, in both treatment groups is highest at day
0 and invariably reduces over the following 3 days.
Patients treated with DHA–PQP reported signiﬁcantly
fewer adverse events on day 1 (P ¼ 0.0006) and day 2
(P ¼ 0.01). By day 3, all symptoms were reported equally
between both groups (Table 5). The most marked differ-
ences for all patients were seen for dizziness where on day 1
of the treatment 61% of the MAS3 group reported this
symptom compared with 41.9% in the DHA–PQP group,
while on day 0 these proportions had been 65.5% and
64.4%, respectively. Similarly, for vomiting, among DHA–
PQP patients, 24.6% vomited on day 0 and 12.5% on day
1, compared with 28.2% and 21.4%, respectively, for
MAS3 and 49.8% of DHA–PQP patients reported anor-
exia on day 0 and 34.5% on day 1 compared with 53.8%
and 47.8%, respectively, for MAS3.
Discussion
This study showed that both DHA–PQP and artesunate–
meﬂoquine were highly efﬁcacious treatments for
Table 4 Adverse events that appeared in
the ﬁrst 3 days after the start of the treat-
ment
Dihydroartemisinin–
piperaquine
Meﬂoquine–
artesunate
Relative risk
(95% CI) P
Dizziness 9/67 (13.4%) 26/72 (36.1%) 2.69 (1.36–5.31) 0.002
Vomiting 14/142 (9.9%) 29/153 (19%) 1.92 (1.06–3.49) 0.03
Nausea 15/90 (16.7%) 29/105 (27.6%) 1.66 (0.95–2.89) 0.07
Anorexia 15/96 (15.6%) 26/101 (25.7%) 1.65 (0.93–2.92) 0.08
Sleeping disorders 16/138 (11.6%) 36/156 (23.1%) 1.80 (1.04–3.13) 0.03
Palpitations 9/127 (7.1%) 23/153 (15%) 2.12 (1.02–4.420 0.04
Blurred vision 10/153 (6.5%) 21/170 (12.4%) 1.89 (0.92–3.89) 0.08
chi squared test.
Table 5 Mean number of adverse events reported by patients
treated with DHA–PQP and MAS3
MAS3 DHA–PQP P
Day 0 6.20 5.85 Ns*
Day 1 5.12 3.86 0.0006
Day 2 2.74 1.91 0.01
Day 3 1.21 1.09 Ns*
chi-squared test.
*Ns ¼ Not signiﬁcant, P > 0.05.
Table 3 Appearance of Plasmodium vivax
and Plasmodium malariae in the 63-day
follow-up period of the trial
No. of cases by day after treatment initiation
Day
7
Day
14
Day
21
Day
28
Day
35
Day
42
Day
49
Day
56
Day
63 Total
DHA–PQP – 1 1 (–) 1 (–) 1 6 14 2 (1) 13 39 (36)
MAS3 – – – – 3 6 10 12 (11) 16 (14) 47 (44)
One case was diagnosed with P. vivax and P. malariae.
Analysis presented for the ITT analysis and values in () for the PP analysis.
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Cambodia. DHA–PQP caused a signiﬁcantly faster fever
and parasite clearance on the ﬁrst day of treatment. These
results conﬁrm the results of other published trials from
Asia (Denis et al. 2002; Ashley et al. 2004, 2005;
Karunajeewa et al. 2004; Tran et al. 2004; Smithuis et al.
2006).
A 3-day regimen of artesunate and meﬂoquine is
currently the national protocol for the treatment of
falciparum malaria in Cambodia. Since the introduction of
this regimen in 2001, it has proved highly efﬁcacious in
routine efﬁcacy surveillance organized by the Ministry of
Health but the frequent occurrence of adverse events
associated with meﬂoquine poses a threat to adherence.
A ﬁxed combination is under development
(http://www.dndi.org) but is not yet available. The need to
prescribe the drugs separately also makes non-adherence
more likely and increases the risk of the emergence of drug
resistance. In terms of adverse events, patients who were
treated with DHA–PQP reported signiﬁcantly less episodes
of vomiting, dizziness, sleeping disorders and palpitations
in the ﬁrst 3 days after the start of the treatment. These are
all well-known side effects of meﬂoquine treatment.
Patients treated with DHA–PQP also reported a signiﬁ-
cantly lower number of adverse events on day 1 and day 2.
The symptoms that were recorded are similar to those of
acute malaria which makes it possible that the superior
tolerability of DHA–PQP is partially explained by the more
rapid fever and parasite clearance. In any case, this is a
favourable effect for patients in terms of overall response
to treatment. Active screening for adverse events using a
symptom questionnaire might have led to some over-
reporting, but we would expect this to be similar in both
groups. We believe that this appreciably better tolerability,
combined with the fact that it is a ﬁxed combination, will
be an important factor in encouraging good adherence
among all patients, although the earlier relief of symptoms
with DHA–PQP might carry the risk of some patients
taking an incomplete treatment course. Emphasis on
enhancing patient treatment literacy and empowerment is
thus necessary to avoid this potential problem. PQP is also
not available as monotherapy which is another advantage
of deploying this combination. The cost of DHA–PQP, at
around 1.2 USD for an adult treatment which is cheaper
than MAS3 (currently around 3 USD for the same
treatment), is likely to make this treatment attractive to
National malaria control programs. The advantages des-
cribed make this combination highly appropriate for
routine use in programme settings. It could be deployed
fairly easily as part of a decentralized outreach strategy
that attempts to bring the treatment of P. falciparum
malaria closer to remote communities.
This trial was conducted using four doses of DHA–PQP
at 0, 8, 24 and 48 h. This is still a slightly complicated
regimen. Research in Thailand in 2005 (Ashley et al. 2005)
reported similarly high efﬁcacy of a once daily regimen
with three doses at 0, 24 and 48 h.
In conclusion, DHA–PQP is a highly efﬁcacious and
better-tolerated ﬁxed dose combination antimalarial which
would be a good alternative to artesunate–meﬂoquine for
the treatment of uncomplicated falciparum malaria in
Cambodia.
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Une e ´tude randomise ´e ouverte pour e ´valuer l’efﬁcacite ´ et la tole ´rance du dihydroarte ´misinine-pipe ´raquine dans le traitement de la malaria
falciparum non complique ´e au Cambodge
objectifs Comparer l’efﬁcacite ´ et la tole ´rance du dihydroarte ´misinine-pipe ´raquine (DHA–PQP) a ` celles d’un re ´gime a ` base de me ´ﬂoquine de trois
jours (MAS3) pour le traitement de la malaria falciparum non complique ´e au Cambodge.
methode Etude Randomise ´e ouverte de non infe ´riorite ´ sur 64 jours.
resultats 464 patients ont e ´te ´ inclus dans l’e ´tude. Les taux gue ´rison au jour 63 ajuste ´s par les re ´sultats du ge ´notypage par la re ´action en chaı ˆne de la
polyme ´rase e ´taient de 97,5% (IC95%: 93.8–99.3) pour le DHA–PQP et de 97,5% (IC95%: 93,8–99,3) pour le MAS3, P ¼ 1. Il n’y avait aucun effet
adverse se ´rieux, mais de fac ¸on signiﬁcative, des e ´pisodes de vomissement (P ¼ 0,03), des vertiges (P ¼ 0,002), des palpitations (P ¼ 0,04), et des
troubles de sommeil (P ¼ 0.03) ont e ´te ´ rapporte ´s dans le groupe du traitement au MAS3, ce qui e ´tait consistant avec les proﬁles d’effets secondaires du
me ´ﬂoquine.
conclusion le DHA–PQP e ´tait aussi efﬁcace que le MAS3, mais bien mieux tole ´re ´, le rendant ainsi plus approprie ´ pour l’usage en routine dans le
cadre d’un programme. Cette combinaison a ` dose ﬁxe de grande efﬁcacite ´,s u ˆre et plus accessible pourrait devenir le traitement de choix pour la malaria
a ` Plasmodium falciparum au Cambodge.
mots cle ´s efﬁcacite ´, tole ´rance, dihydroarte ´misinine-pipe ´raquine, malaria falciparum
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258 ª 2007 Blackwell Publishing LtdEstudio abierto y aleatorizado para evaluar la eﬁcacia y la tolerabilidad de la dihidroartemisinina-piperaquina para el tratamiento de la malaria no
complicada por falciparum en Cambodia
objetivos Comparar la eﬁcacia y la tolerabilidad de la dihidroartemisinina-piperaquina (DHA–PQP) con la de un re ´gimen de 3 dı ´as de meﬂoquina
(MAS3), para el tratamiento de la malaria no complicada por falciparum en Cambodia
me ´todo Estudio aleatorizado, abierto, de no-inferioridad, durante 64 dı ´as.
resultados Se incluyeron 464 pacientes en el estudio. Las tasas de curacio ´ne ne ld ı ´a 63, ajustadas por genotipaje mediante PCR, fueron del 97.5%
(95% IC: 93.8–99.3) para DHA–PQP y del 97.5% (95%IC: 93.8–99.3) para MAS3, P ¼ 1. No se observaron eventos adversos serios, pero si se reporto ´
un nu ´mero signiﬁcativo de episodios de vo ´mitos (P ¼ 0.03), mareos (P ¼ 0.002), palpitaciones (P ¼ 0.04), y deso ´rdenes del sue,no (P ¼ 0.03) entre el
grupo de tratamiento con MAS3, algo consistente con el perﬁl de efectos secundarios de la meﬂoquina.
conclusiones La DHA–PQP fue tan eﬁcaz como la MAS3, adema ´s de ser mejor tolerada, siendo ma ´s apropiada para el uso dentro del marco de un
programa de rutina. Esta combinacio ´n de dosis ﬁja, altamente eﬁcaz, segura y ma ´s asequible, podrı ´a convertirse en el tratamiento de eleccio ´n para
malaria por Plasmodium falciparum en Cambodia.
palabras clave eﬁcacia, tolerabilidad, dihidroartemisinina-piperaquina, malaria por falciparum
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